|
Iranian Journal of Pharmacology and Therapeutics
Razi Institute for Drug Research (RIDR) of Iran University of Medical Sciences and Health Services (IUMS)
ISSN: 1735-2657
Vol. 1, Num. 2, 2002, pp. 37-37
|
Iranian Journal of Pharmacology & Therapeutics, Vol. 1, No. 2, 2002, , pp. 37
Proceedings
Lactoferrin as a Marker of Systemic Inflammatory Response
E.V. Grigoriev, Yu.A. Churlyaev, O.F. Lykova, N.A. Zorin and E.N. Denisov
Department of Anesthesiology, Institute of Postgraduate Education, Novokuzneck,
Russia
Invited Speaker: E.V. Grigoriev, Department of Anesthesiology, Institute
of Postgraduate Education, Novokuzneck, Russia. E-mail: grigoriev@nvkz.kuzhass.net
Code Number: pt02015
ABSTRACT
Materials and methods. 51 patients, who were ill with generalized peritonitis,
went through a prospective randomized research. They were randomized on groups
depending on the objective score SAPS (1984): 29 survived people (53%) and
22 people with favorable end (47%). Intensive care and surgical tactics standardized
patients. Lactoferrin (LF) as modulator of systemic inflammatory response (SIR)
was assessed by immunoferment analysis. Statistical processing was done McNemar
test.
Results and discussion. In initial condition dynamics of this laboratory marker
defined a group with favorable end as patients with granulocytes activation
[1]. On the first 24 hours level of LF was marked twice above values of second
group (95% confidence interval (CI) 1670-2024 ng/ml; p<0.05). Then content
of LF was increased for certain in highest limit of rate (95% CI 1104-1310;
p<0.001). LF level in group with nonfavourable end was remained in lowered
figures. It was differ with such in group of comparison for certain (95% CI
811-921 ng/ml; p<0.05). This situation can be explained as repression of
nonspecific resistance on repeated effects of endotoxins. Positive connection
of LF indices with facts of SIR (r=0.457; p<0.05) can serve as proof of
granulocyte?s activation in group with favorable end [2].
- Bistrian BR. Crit Care Med. 1999; 27(3); 452-453.
- Nuijens JH, Abbink JJ. Wachtfoggel YT. J Lab Clin Med. 1992; 112(2);
159-168.
Powerpoint
presentation available in PDF format only
Copyright © 2002 by Razi Institute for Drug
Research (RIDR)
|
